[go: up one dir, main page]

US20030007963A1 - Treatment of pompe's disease - Google Patents

Treatment of pompe's disease Download PDF

Info

Publication number
US20030007963A1
US20030007963A1 US09/454,711 US45471199A US2003007963A1 US 20030007963 A1 US20030007963 A1 US 20030007963A1 US 45471199 A US45471199 A US 45471199A US 2003007963 A1 US2003007963 A1 US 2003007963A1
Authority
US
United States
Prior art keywords
glucosidase
dosage
patient
administered
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/454,711
Other languages
English (en)
Inventor
Johannes Van Bree
Edna Venneker
David Meeker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharming BV
Genzyme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22337648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20030007963(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US09/454,711 priority Critical patent/US20030007963A1/en
Application filed by Individual filed Critical Individual
Assigned to GENZYME CORPORATION reassignment GENZYME CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MEEKER, DAVID P.
Assigned to PHARMING B.V. reassignment PHARMING B.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VAN BREE, JOHANNES B.M.M., VENNEKER, EDNA H.G.
Publication of US20030007963A1 publication Critical patent/US20030007963A1/en
Priority to US10/611,598 priority patent/US7351410B2/en
Assigned to PHARMING INTELLECTUAL PROPERTY B.V. reassignment PHARMING INTELLECTUAL PROPERTY B.V. CORRECTED COVER SHEET TO CORRECT ASSIGNEE NAME, PREVIOUSLY RECORDED AT REEL/FRAME 010749/0076 (ASSIGNMENT OF ASSIGNOR'S INTEREST) Assignors: VENNEKER, EDNA H.G., VAN BREE, JOHANNES B.M.M.
Assigned to GENZYME CORPORATION reassignment GENZYME CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PHARMING INTELLECTUAL PROPERTY B.V.
Priority to US12/012,003 priority patent/US7655226B2/en
Priority to US12/633,932 priority patent/US20100092449A1/en
Priority to US13/333,052 priority patent/US20130039901A1/en
Priority to US13/886,573 priority patent/US20140037611A1/en
Priority to US14/863,333 priority patent/US20160243203A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases

Definitions

  • the present invention resides in the fields of recombinant genetics, and medicine, and is directed to enzyme-replacement therapy of patients with Pompe's disease.
  • lysosomal proteins are synthesized in the endoplasmic reticulum and transported to the Golgi apparatus. However, unlike most other secretory proteins, the lysosomal proteins are not destined for secretion into extracellular fluids but into an intracellular organelle. Within the Golgi, lysosomal proteins undergo special processing to equip them to reach their intracellular destination. Almost all lysosomal proteins undergo a variety of posttranslational modifications, including glycosylation and phosphorylation via the 6′ position of a terminal mannose group. The phosphorylated mannose residues are recognized by specific receptors on the inner surface of the Trans Golgi Network.
  • the lysosomal proteins bind via these receptors, and are thereby separated from other secretory proteins. Subsequently, small transport vesicles containing the receptor-bound proteins are pinched off from the Trans Golgi Network and are targeted to their intracellular destination. See generally Kornfeld, Biochem. Soc. Trans. 18, 367-374 (1990).
  • lysosomal diseases there are over thirty lysosomal diseases, each resulting from a deficiency of a particular lysosomal protein, usually as a result of genetic mutation. See, e.g., Cotran et al., Robbins Pathologic Basis of Disease (4th ed. 1989) (incorporated by reference in its entirety for all purposes).
  • the deficiency in the lysosomal protein usually results in harmful accumulation of a metabolite.
  • Glycogen storage disease type II (GSD II; Pompe disease; acid maltase deficiency) is caused by deficiency of the lysosomal enzyme acid ⁇ -glucosidase (acid maltase).
  • GSD II Pompe disease; acid maltase deficiency
  • ⁇ -glucosidase acid maltase
  • Two clinical forms are distinguished: early onset infantile and late onset, juvenile and adult. Infantile GSD II has its onset shortly after birth and presents with progressive muscular weakness and cardiac failure. This clinical variantis usually fatal within the first two years of life. Symptoms in the late onset in adult and juvenile patients occur later in life, and only skeletal muscles are involved. The patients eventually die due to respiratory insufficiency. Patients may exceptionally survive for more than six decades.
  • both the duration of treatment, and/or the amount of enzyme administered were insufficient (3-5).
  • Production of lysosomal enzymes from natural sources such as human urine and bovine testis is in theory possible, but gives low yields, and the enzyme purified is not necessarily in a form that can be taken up by tissues of a recipient patient.
  • the invention provides methods of treating patients for Pompe's disease using human acid alpha glucosidase.
  • the invention provides methods of treating a patient with Pompe's disease. Such methods entail administering to the patient a therapeutically effective amount of human acid alpha glucosidase.
  • the dosage is preferably at least 10 mg/kg body weight per week. In some methods, the dosage is at least 60 mg/kg body weight per week or at least 120 mg/kg body weight per week. In some methods, such dosages are administered on a single occasion per week and in other methods on three occasions per week. In some methods, the treatment is containued for ate least 24 weeks. Adminstration is preferably intravenous.
  • the human acid alpha glucosidase is preferably obtained in the milk of a nonhuman transgenic mammal, and is preferably predominatly in a 110 kD form.
  • the methods can be used for treating patients with infantile, juvenile or adult Pompe's disease.
  • infantile Pompe's disease efficacy is indicated by a patient surviving to be at least one year old.
  • levels of human acid alpha glucosidase are monitored in the recuouebt patient.
  • a second dosage of human acid alpha glucosidase can be administered if the level of alpha-glucosidase falls below a threshold value in the patient.
  • the human alpha glucosidase is administered intravenously and the rate of administration increases during the period of administration.
  • the rate of administration increases by at least a factor of ten during the period of administration.
  • the rate of administration increases by at least a factor of ten within a period of five hours.
  • the patient is administered a series of at least four dosages, each dosage at a higher strength than the previous dosage.
  • the dosages are a first dosage of 0.03-3 mg/kg/hr, a second dosage of 0.3-12 mg/kg/hr, a third dosage of 1-30 mg/kg/hr and a fourth dosage of 2-60 mg/kg/hr.
  • the dosages are a first dosage of 0.1-1 mg/kg/hr, a second dosage of 1-4 mg/kg/hr, a third dosage of 3-10 mg/kg/hr and a fourth dosage of 6-20 mg/kg/hr. In some methods, the dosages are a first dosage of 0.25-4 mg/kg/hr, a second dosage of 0.9-1.4 mg/kg/hr, a third dosage of 3.6-5.7 mg/kg/hr and a fourth dosage of 7.2-11.3 mg/kg/hr.
  • the dosages are a first dosage of 0.3 mg/kg/hr, a second dosage of 1 mg/kg/hr, a third dosage of 4 mg/kg/hr and a fourth dosage of 12 mg/kg/hr. In some methods, the first, second, third and fourth dosages are each administered for periods of 15 min to 8 hours.
  • the first, second, third and fourth dosages are administered for periods of 1 hr, 1 hr, 0.5 hr and 3 hr respectively.
  • the invention provides a pharmaceutical composition comprising human acid alpha glucosidase, human serum albumin, and a sugar in a physiologically acceptable buffer in sterile form.
  • Some such compositions comprise human acid alpha glucosidase, human serum albumin, and glucose in sodium phosphate buffer.
  • Some compositions comprise alpha glucosidase, mannitol and sucrose in an aqueous solution.
  • the sugar comprises mannitol and sucrose and the concentration of mannitol is 1-3% w/w of the aqueous solution and the concentration of sucrose is 0.1 to 1% w/w of the aqueous solution.
  • the concentration of mannitol is 2% w/w and the concentration of sucrose is 0.5% w/w.
  • the invention further provides a lyophilized composition produced by lyophilizing a pharmaceutical composition comprising human acid glucosidase, mannitol and sucrose in aqueous solution.
  • a composition can be prepared by lyophilizing a first composition comprising human acid alpha-glucosidase, mannitol, sucrose and an aqueous solution to produce a second composition; and reconstituting the lyophilized composition in saline to produce a third composition.
  • the human acid alpha-glucosidase is at 5 mg/ml in both the first and third composition
  • the mannitol is at 2 mg/ml in the first composition
  • the sucrose is at 0.5 mg/ml in the first composition
  • the saline used in the reconstituting step is 0.9% w/w.
  • FIG. 1 A transgene containing acid ⁇ -glucosidase cDNA.
  • the ⁇ s1-casein exons are represented by open boxes; ⁇ -glucosidase cDNA is represented by a shaded box.
  • the ⁇ s1-casein intron and flanking sequences are represented by a thick line.
  • a thin line represents the IgG acceptor site.
  • the transcription initiation site is marked (1 ⁇ ), the translation initiation site (ATG), the stop codon (TAG) and the polyadenylation site (pA).
  • FIG. 2 panels A, B, C: Three transgenes containing acid ⁇ -glucosidase genomic DNA. Dark shaded areas are ⁇ s1 casein sequences, open boxes represent acids ⁇ -glucosidase exons, and the thin line between the open boxes represents ⁇ -glucosidase introns. Other symbols are the same as in FIG. 1.
  • FIG. 3 panels A, B, C: Construction of genomic transgenes.
  • the ⁇ -glucosidase exons are represented by open boxes; the ⁇ -glucosidase introns and nontranslated sequences are indicated by thin lines.
  • the pKUN vector sequences are represented by thick lines.
  • FIG. 4 Detection of acid ⁇ -glucosidase in milk of transgenic mice by Western blotting.
  • substantially identical or “substantial homology” means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 65 percent sequence identity, preferably at least 80 or 90 percent sequence identity, more preferably at least 95 percent sequence identity or more (e.g., 99 percent sequence identity). Preferably, residue positions which are not identical differ by conservative amino acid substitutions.
  • substantially pure or “isolated” means an object species has been identified and separated and/or recovered from a component of its natural environment.
  • the object species is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all macromolecular species present.
  • a substantially pure composition will comprise more than about 80 to 90 percent by weight of all macromolecular species present in the composition.
  • the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of derivatives of a single macromolecular species.
  • a DNA segment is operably linked when placed into a functional relationship with another DNA segment.
  • DNA for a signal sequence is operably linked to DNA encoding a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it stimulates the transcription of the sequence.
  • DNA sequences that are operably linked are contiguous, and in the case of a signal sequence both contiguous and in reading phase.
  • enhancers need not be contiguous with the coding sequences whose transcription they control. Linking is accomplished by ligation at convenient restriction sites or at adapters or linkers inserted in lieu thereof.
  • exogenous DNA segment is one foreign to the cell, or homologous to a DNA segment of the cell but in an unnatural position in the host cell genome. Exogenous DNA segments are expressed to yield exogenous polypeptides.
  • transgenic mammal all, or substantially all, of the germline and somatic cells contain a transgene introduced into the mammal or an ancestor of the mammal at an early embryonic stage.
  • the invention provides transgenic nonhuman mammals secreting a lysosomal protein into their milk. Secretion is achieved by incorporation of a transgene encoding a lysosomal protein and regulatory sequences capable of targeting expression of the gene to the mammary gland.
  • the transgene is expressed, and the expression product posttranslationally modified within the mammary gland, and then secreted in milk.
  • the posttranslational modification can include steps of glycosylation and phosphorylation to produce a mannose-6 phosphate containing lysosomal protein.
  • the invention provides transgenic nonhuman mammals expressing DNA segments containing any of the more than 30 known genes encoding lysosomal enzymes and other types of lysosomal proteins, including ⁇ -glucosidase, ⁇ -L-iduronidase, iduronate-sulfate sulfatase, hexosaminidase A and B, ganglioside activator protein, arylsulfatase A and B, iduronate sulfatase, heparan N-sulfatase, galacto-ceramidase, ⁇ -galactosylceramidase A, sphingomyelinase, ⁇ -fucosidase, ⁇ -mannosidase, aspartylglycosamine amide hydrolase, acid lipase, N-acetyl- ⁇ -D-glucosamine-6-sulphate sulfatase, ⁇ -and
  • Transgenic mammals expressing allelic, cognate and induced variants of any of the known lysosomal protein gene sequences are also included. Such variants usually show substantial sequence identity at the amino acid level with known lysosomal protein genes. Such variants usually hybridize to a known gene under stringent conditions or crossreact with antibodies to a polypeptide encoded by one of the known genes.
  • genomic and cDNA sequences are available from GenBank. To the extent that additional cloned sequences of lysosomal genes are required, they may be obtained from genomic or cDNA libraries (preferably human) using known lysosomal protein DNA sequences or antibodies to known lysosomal proteins as probes.
  • lysosomal proteins are preferably processed to have the same or similar structure as naturally occurring lysosomal proteins.
  • Lysosomal proteins are glycoproteins that are synthesized on ribosomes bound to the endoplasmic reticulum (RER). They enter this organelle co-translationally guided by an N-terminal signal peptide (Ng et al., Current Opinion in Cell Biology 6, 510-516 (1994)).
  • the N-linked glycosylation process starts in the RER with the en bloc transfer of the high-mannose oligosaccharide precursor Glc3Man9 GlcNAc2 from a dolichol carrier.
  • Carbohydrate chain modification starts in the RER and continue in the Golgi apparatus with the removal of the three outermost glucose residues by glycosidases I and II.
  • Phosphorylation is a two-step procedure in which first N-acetyl-gluco-samine-1-phosphate is coupled to select mannose groups by a lysosomal protein specific transferase, and second, the N-acetyl-gluco-samine is cleaved by a diesterase (Goldberg et al., Lysosomes: Their Role in Protein Breakdown (Academic Press Inc., London, 1987), pp. 163-191).
  • the proteolytic processing of acid ⁇ -glucosidase is complex and involves a series of steps in addition to cleavage of the signal peptide taking place at various subcellular locations. Polypeptides are cleaved off at both the N and C terminal ends, whereby the specific catalytic activity is increased.
  • the main species recognized are a 110/100 kD precursor, a 95 kD intermediate and 76 kD and 70 kD mature forms.
  • Authentic processing to generate lysosomal proteins phosphorylated at the 6′ position of the mannose group can be tested by measuring uptake of a substrate by cells bearing a receptor for mannose 6-phosphate. Correctly modified substrates are taken up faster than unmodified substrates, and in a manner whereby uptake of the modified substrate can be competitively inhibited by addition of mannose 6-phosphate.
  • Transgenes are designed to target expression of a recombinant lysosomal protein to the mammary gland of a transgenic nonhuman mammal harboring the transgene.
  • the basic approach entails operably linking an exogenous DNA segment encoding the protein with a signal sequence, a promoter and an enhancer.
  • the DNA segment can be genomic, minigene (genomic with one or more introns omitted), cDNA, a YAC fragment, a chimera of two different lysosomal protein genes, or a hybrid of any of these. Inclusion of genomic sequences generally leads to higher levels of expression.
  • intronic sequences In genomic constructs, it is not necessary to retain all intronic sequences. For example, some intronic sequences can be removed to obtain a smaller transgene facilitating DNA manipulations and subsequent microinjection. See Archibald et al., WO 90/05188 (incorporated by reference in its entirety for all purposes). Removal of some introns is also useful in some instances to reduce expression levels and thereby ensure that posttranslational modification is substantially complete. In other instances excluding an intron such as intron one from the genomic sequence of acid ⁇ -glucosidase leads to a higher expression of the mature enzyme. It is also possible to delete some or all of noncoding exons. In some transgenes, selected nucleotides in lysosomal protein encoding sequences are mutated to remove proteolytic cleavage sites.
  • the species from which the DNA segment encoding a lysosomal protein sequence is obtained is preferably human. Analogously if the intended use were in veterinary therapy (e.g., on a horse, dog or cat), it is preferable that the DNA segment be from the same species.
  • the promoter and enhancer are from a gene that is exclusively or at least preferentially expressed in the mammary gland (i.e., a mammary-gland specific gene).
  • Preferred genes as a source of promoter and enhancer include ⁇ -casein, ⁇ -casein, ⁇ S1-casein, ⁇ S2-casein, ⁇ -lactoglobulin, whey acid protein, and ⁇ -lactalbumin.
  • the promoter and enhancer are usually but not always obtained from the same mammary-gland specific gene. This gene is sometimes but not necessarily from the same species of mammal as the mammal into which the transgene is to be expressed. Expression regulation sequences from other species such as those from human genes can also be used.
  • the signal sequence must be capable of directing the secretion of the lysosomal protein from the mammary gland.
  • Suitable signal sequences can be derived from mammalian genes encoding a secreted protein.
  • the natural signal sequences of lysosomal proteins are suitable, notwithstanding that these proteins are normally not secreted but targeted to an intracellular organelle.
  • preferred sources of signal sequences are the signal sequence from the same gene as the promoter and enhancer are obtained.
  • additional regulatory sequences are included in the transgene to optimize expression levels.
  • sequences include 5′ flanking regions, 5′ transcribed but untranslated regions, intronic sequences, 3′ transcribed but untranslated regions, polyadenylation sites, and 3′ flanking regions.
  • sequences are usually obtained either from the mammary-gland specific gene from which the promoter and enhancer are obtained or from the lysosomal protein gene being expressed. Inclusion of such sequences produces a genetic milieu simulating that of an authentic mammary gland specific gene and/or that of an authentic lysosomal protein gene. This genetic milieu results in some cases (e.g., bovine ⁇ S1-casein) in higher expression of the transcribed gene.
  • 3′ flanking regions and untranslated regions are obtained from other heterologous genes such as the ⁇ -globin gene or viral genes.
  • heterologous genes such as the ⁇ -globin gene or viral genes.
  • the inclusion of 3′ and 5′ untranslated regions from a lysosomal protein gene, or other heterologous gene can also increase the stability of the transcript.
  • about 0.5, 1, 5, 10, 15, 20 or 30 kb of 5′ flanking sequence is included from a mammary specific gene in combination with about 1, 5, 10, 15, 20 or 30 kb or 3′ flanking sequence from the lysosomal protein gene being expressed.
  • the protein is expressed from a cDNA sequence, it is advantageous to include an intronic sequence between the promoter and the coding sequence.
  • the intronic sequence is preferably a hybrid sequence formed from a 5′ portion from an intervening sequence from the first intron of the mammary gland specific region from which the promoter is obtained and a 3′ portion from an intervening sequence of an IgG intervening sequence or lysosomal protein gene. See DeBoer et al., WO 91/08216 (incorporated by reference in its entirety for all purposes).
  • a preferred transgene for expressing a lysosomal protein comprises a cDNA-genomic hybrid lysosomal protein gene linked 5′ to a casein promoter and enhancer.
  • the hybrid gene includes the signal sequence, coding region, and a 3′ flanking region from the lysosomal protein gene.
  • the cDNA segment includes an intronic sequence between the 5′ casein and untranslated region of the gene encoding the lysosomal protein.
  • corresponding cDNA and genomic segments can also be fused at other locations within the gene provided a contiguous protein can be expressed from the resulting fusion.
  • genomic lysosomal protein segment linked 5′ to casein regulatory sequences.
  • the genomic segment is usually contiguous from the 5′ untranslated region to the 3′ flanking region of the gene.
  • the genomic segment includes a portion of the lysosomal protein 5′ untranslated sequence, the signal sequence, alternating introns and coding exons, a 3′ untranslated region, and a 3′ flanking region.
  • the genomic segment is linked via the 5′ untranslated region to a casein fragment comprising a promoter and enhancer and usually a 5′ untranslated region.
  • DNA sequence information is available for all of the mammary gland specific genes listed above, in at least one, and often several organisms. See, e.g., Richards et al., J. Biol. Chem. 256, 526-532 (1981) ( ⁇ -lactalbumin rat); Campbell et al., Nucleic Acids Res. 12, 8685-8697 (1984) (rat WAP); Jones et al., J. Biol. Chem. 260, 7042-7050 (1985)) (rat ⁇ -casein); Yu-Lee & Rosen, J. Biol. Chem. 258, 10794-10804 (1983) (rat ⁇ -casein)); Hall, Biochem. J.
  • lysosomal proteins in the milk from transgenes can be influenced by co-expression or functional inactivation (i.e., knock-out) of genes involved in post translational modification and targeting of the lysosomal proteins.
  • the data in the Examples indicate that surprisingly mammary glands already express modifying enzymes at sufficient quantities to obtain assembly and secretion of mannose 6-phosphate containing proteins at high levels.
  • Such transgenes are constructed employing similar principles to those discussed above with the processing enzyme coding sequence replacing the lysosomal protein coding sequence in the transgene.
  • the secretion signal sequence linked to the lysosomal protein coding sequence is replaced with a signal sequence that targets the processing enzyme to the endoplasmic reticulum without secretion.
  • the signal sequences naturally associated with these enzymes are suitable.
  • transgenes described above are introduced into nonhuman mammals.
  • Most nonhuman mammals including rodents such as mice and rats, rabbits, ovines such as sheep and goats, porcines such as pigs, and bovines such as cattle and buffalo, are suitable.
  • Bovines offer an advantage of large yields of milk, whereas mice offer advantages of ease of transgenesis and breeding. Rabbits offer a compromise of these advantages.
  • a rabbit can yield 100 ml milk per day with a protein content of about 14% (see Buhler et al., Bio/Technology 8, 140 (1990)) (incorporated by reference in its entirety for all purposes), and yet can be manipulated and bred using the same principles and with similar facility as mice.
  • Nonviviparous mammals such as a spiny anteater or duckbill platypus are typically not employed.
  • transgenes are introduced into the pronuclei of fertilized oocytes.
  • animals such as mice and rabbits
  • fertilization is performed in vivo and fertilized ova are surgically removed.
  • In vitro fertilization permits a transgene to be introduced into substantially synchronous cells at an optimal phase of the cell cycle for integration (not later than S-phase).
  • Transgenes are usually introduced by microinjection. See U.S. Pat. No. 4,873,292.
  • Fertilized oocytes are then cultured in vitro until a pre-implantation embryo is obtained containing about 16-150 cells.
  • the 16-32 cell stage of an embryo is described as a morula.
  • Pre-implantation embryos containing more than 32 cells are termed blastocysts. These embryos show the development of a blastocoele cavity, typically at the 64 cell stage.
  • Methods for culturing fertilized oocytes to the pre-implantation stage are described by Gordon et al., Methods Enzymol. 101, 414 (1984); Hogan et al., Manipulation of the Mouse Embryo: A Laboratory Manual, C.S.H.L.
  • pre-implantation embryos are stored frozen for a period pending implantation.
  • Pre-implantation embryos are transferred to the oviduct of a pseudopregnant female resulting in the birth of a transgenic or chimeric animal depending upon the stage of development when the transgene is integrated. Chimeric mammals can be bred to form true germline transgenic animals.
  • transgenes can be introduced into embryonic stem cells (ES). These cells are obtained from preimplantation embryos cultured in vitro. Bradley et al., Nature 309, 255-258 (1984) (incorporated by reference in its entirety for all purposes). Transgenes can be introduced into such cells by electroporation or microinjection. Transformed ES cells are combined with blastocysts from a non-human animal. The ES cells colonize the embryo and in some embryos form the germline of the resulting chimeric animal. See Jaenisch, Science, 240, 1468-1474 (1988) (incorporated by reference in its entirety for all purposes). Alternatively, ES cells can be used as a source of nuclei for transplantation into an enucleated fertilized oocyte giving rise to a transgenic mammal.
  • ES embryonic stem cells
  • the transgenes can be introduced simultaneously using the same procedure as for a single transgene.
  • the transgenes can be initially introduced into separate animals and then combined into the same genome by breeding the animals.
  • a first transgenic animal is produced containing one of the transgenes.
  • a second transgene is then introduced into fertilized ova or embryonic stem cells from that animal.
  • transgenes whose length would otherwise exceed about 50 kb, are constructed as overlapping fragments. Such overlapping fragments are introduced into a fertilized oocyte or embryonic stem cell simultaneously and undergo homologous recombination in vivo. See Kay et al., WO 92/03917 (incorporated by reference in its entirety for all purposes).
  • Transgenic mammals of the invention incorporate at least one transgene in their genome as described above.
  • the transgene targets expression of a DNA segment encoding a lysosomal protein at least predominantly to the mammary gland.
  • the mammary glands are capable of expressing proteins required for authentic posttranslation processing including steps of oligosaccharide addition and phosphorylation. Processing by enzymes in the mammary gland results in phosphorylation of the 6′ position of mannose groups.
  • Lysosomal proteins can be secreted at high levels of at least 10, 50, 100, 500, 1000, 2000, 5000 or 10,000 ⁇ g/ml. Surprisingly, the transgenic mammals of the invention exhibit substantially normal health. Secondary expression of lysosomal proteins in tissues other than the mammary gland does not occur to an extent sufficient to cause deleterious effects. Moreover, exogenous lysosomal protein produced in the mammary gland is secreted with sufficient efficiency that no significant problem is presented by deposits clogging the secretory apparatus.
  • transgenic mammals can begin producing milk, of course, varies with the nature of the animal. For transgenic bovines, the age is about two-and-a-half years naturally or six months with hormonal stimulation, whereas for transgenic mice the age is about 5-6 weeks. Of course, only the female members of a species are useful for producing milk. However, transgenic males are also of value for breeding female descendants. The sperm from transgenic males can be stored frozen for subsequent in vitro fertilization and generation of female offspring.
  • Transgenic adult female mammals produce milk containing high concentrations of exogenous lysosomal protein.
  • the protein can be purified from milk, if desired, by virtue of its distinguishing physical and chemical properties, and standard purification procedures such as precipitation, ion exchange, molecular exclusion or affinity chromatography. See generally Scopes, Protein Purification (Springer-Verlag, New York, 1982).
  • Purification of human acid ⁇ -glucosidase from milk can be carried out by defatting of the transgenic milk by centrifugation and removal of the fat, followed by removal of caseins by high speed centrifugation followed by dead-end filtration (i.e., dead-end filtration by using successively declining filter sizes) or cross-flow filtration, or; removal of caseins directly by cross-flow filtration.
  • Human acid ⁇ -glucosidase is purified by chromatography, including Q Sepharose FF (or other anion-exchange matrix), hydrophobic interaction chromatography (HIC), metal-chelating Sepharose, or lectins coupled to Sepharose (or other matrices).
  • Q Sepharose Fast Flow chromatography may be used to purify human acid ⁇ -glucosidase present in filtered whey or whey fraction as follows: a Q Sepharose Fast Flow (QFF; Pharmacia) chromatography (Pharmacia XK-50 column, 15 cm bed height; 250 cm/hr flow rate) the column was equilibrated in 20 mM sodiumphosphate buffer, pH 7.0 (buffer A); the S/D-incubated whey fraction (about 500 to 600 ml) is loaded and the column is washed with 4-6 column volumes (cv) of buffer A (20 mM sodium phosphate buffer, pH 7.0). The human acid ⁇ -glucosidase fraction is eluted from the Q FF column with 2-3 cv buffer A, containing 100 mM NaCl.
  • QFF Q Sepharose Fast Flow
  • the Q FF Sepharose human acid ⁇ -glucosidase containing fraction can be further purified using Phenyl Sepharose High Performance chromatography. For example, 1 vol. of 1M ammonium sulphate is added to the Q FF Sepharose human acid ⁇ -glucosidase eluate while stirring continuously.
  • Phenyl HP (Pharmacia) column chromatography (Pharmacia XK-50 column, 15 cm bed height; 150 cm/hr flow rate) is then done at room temperature by equilibrating the column in 0.5 M ammonium sulphate, 50 mM sodiumphosphate buffer pH 6.0 (buffer C), loading the 0.5 M ammoniumsulphate-incubated human acid ⁇ -glucosidase eluate (from Q FF Sepharose), washing the column with 2-4 cv of buffer C, and eluting the human acid ⁇ -glucosidase was eluted from the Phenyl HP column with 3-5 cv buffer D (50 mM sodiumphosphate buffer at pH 6.0).
  • Alternative methods and additional methods for further purifying human acid ⁇ -glucosidase will be apparent to those of skill. For example, see United Kingdom patent application 998 07464.4 (incorporated by reference in its entirety for all purposes).
  • the recombinant lysosomal proteins produced according to the invention find use in enzyme replacement therapeutic procedures.
  • a patient having a genetic or other deficiency resulting in an insufficiency of functional lysosomal enzyme can be treated by administering exogenous enzyme to the patient.
  • Patients in need of such treatment can be identified from symptoms (e.g., Hurler's syndrome symptoms include Dwarfism, corneal clouding, hepatosplenomegaly, valvular lesions, coronary artery lesions, skeletal deformities, joint stiffness and progressive mental retardation).
  • patients can be diagnosed from biochemical analysis of a tissue sample to reveal excessive accumulation of a characteristic metabolite processed by a particular lysosomal enzyme or by enzyme assay using an artificial or natural substrate to reveal deficiency of a particular lysosomal enzyme activity.
  • diagnosis can be made by measuring the particular enzyme deficiency or by DNA analysis before occurrence of symptoms or excessive accumulation of metabolites (Scriver et al., supra, chapters on lysosomal storage disorders). All of the lysosomal storage diseases are hereditary. Thus, in offspring from families known to have members suffering from lysosomal diseases, it is sometimes advisable to commence prophylactic treatment even before a definitive diagnosis can be made.
  • lysosomal enzymes are administered in purified form together with a pharmaceutical carrier as a pharmaceutical composition.
  • a pharmaceutical carrier can be any compatible, nontoxic substance suitable to deliver the polypeptides to the patient.
  • Sterile water, alcohol, fats, waxes, and inert solids may be used as the carrier.
  • Pharmaceutically-acceptable adjuvants, buffering agents, dispersing agents, and the like, may also be incorporated into the pharmaceutical compositions.
  • the concentration of the enzyme in the pharmaceutical composition can vary widely, i.e., from less than about 0.1% by weight, usually being at least about 1% by weight to as much as 20% by weight or more.
  • the active ingredient can be administered in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions.
  • Active component(s) can be encapsulated in gelatin capsules together with inactive ingredients and powdered carriers, such as glucose, lactose, sucrose, mannitol, starch, cellulose or cellulose derivatives, magnesium stearate, stearic acid, sodium saccharin, talcum, magnesium carbonate and the like.
  • inactive ingredients examples include red iron oxide, silica gel, sodium lauryl sulfate, titanium dioxide, edible white ink and the like.
  • Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric-coated for selective disintegration in the gastrointestinal tract.
  • Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
  • a typical composition for intravenous infusion could be made up to contain 100 to 500 ml of sterile 0.9% NaCl or 5% glucose optionally supplemented with a 20% albumin solution and 100 to 500 mg of an enzyme.
  • a typical pharmaceutical compositions for intramuscular injection would be made up to contain, for example, 1 ml of sterile buffered water and 1 to 10 mg of the purified alpha glucosidase of the present invention.
  • Methods for preparing parenterally administrable compositions are well known in the art and described in more detail in various sources, including, for example, Remington's Pharmaceutical Science (15th ed., Mack Publishing, Easton, Pa., 1980) (incorporated by reference in its entirety for all purposes).
  • AGLU can be formulated in 10 mM sodium phosphate buffer pH 7.0. Small amounts of ammonium sulphate are optionally present ( ⁇ 10 mM).
  • the enzyme is typically kept frozen at about ⁇ 70° C., and thawed before use. Alternatively, the enzyme may be stored cold (e.g., at about 4° C. to 8° C.) in solution.
  • AGLU solutions comprise a buffer (e.g., sodium phosphate, potassium phosphate or other physiologically acceptable buffers), a simple carbohydrate (e.g., sucrose, glucose, maltose, mannitol or the like), proteins (e.g., human serum albumin), and/or surfactants (e.g., polysorbate 80 (Tween-80), cremophore-EL, cremophore-R, labrofil, and the like).
  • a buffer e.g., sodium phosphate, potassium phosphate or other physiologically acceptable buffers
  • a simple carbohydrate e.g., sucrose, glucose, maltose, mannitol or the like
  • proteins e.g., human serum albumin
  • surfactants e.g., polysorbate 80 (Tween-80), cremophore-EL, cremophore-R, labrofil, and the like.
  • AGLU can also be stored in lyophilized form.
  • AGLU can be formulated in a solution containing mannitol, and sucrose in a phosphate buffer.
  • the concentration of sucrose should be sufficient to prevent aggregation of AGLU on reconstitution.
  • the concentration of mannitol should be sufficient to significantly reduce the time otherwise needed for lyophilization.
  • the concentrations of mannitol and sucrose should, however, be insufficient to cause unacceptable hypertonicity on reconstitution. Concentrations of mannitol and sucrose of 1-3 mg/ml and 0.1-1.0 mg/ml respectively are suitable.
  • Preferred concentrations are 2 mg/ml mannitol and 0.5 mg/ml sucrose.
  • AGLU is preferably at 5 mg/ml before lyophilization and after reconstitution. Saline preferably at 0.9% is a preferred solution for reconstitution.
  • impurities For AGLU purified from rabbit milk, a small amount of impurities (e.g., up to about 5%) can be tolerated. Possible impurities may be present in the form of rabbit whey proteins. Other possible impurities are structural analogues (e.g., oligomers and aggregates) and truncations of AGLU. Current batches indicate that the AGLU produced in transgenic rabbits is >95% pure. The largest impurities are rabbit whey proteins, although on gel electrophoresis, AGLU bands of differing molecular weights are also seen.
  • Infusion solutions should be prepared aseptically in a laminar air flow hood. The appropriate amount of AGLU should be removed from the freezer and thawed at room temperature. Infusion solutions can be prepared in glass infusion bottles by mixing the appropriate amount of AGLU finished product solution with an adequate amount of a solution containing human serum albumin (HSA) and glucose. The final concentrations can be 1% HSA and 4% glucose for 25-200 mg doses and 1% HSA and 4% glucose for 400-800 mg doses. HSA and AGLU can be filtered with a 0.2 ⁇ m syringe filter before transfer into the infusion bottle containing 5% glucose. Alternatively, AGLU can be reconstituted in saline solution, preferably 0.9% for infusion. Solutions of AGLU for infusion have been shown to be stable for up to 7 hours at room temperature. Therefore the AGLU solution is preferably infused within seven hours of preparation.
  • HSA human serum albumin
  • the present invention provides effective methods of treating Pompe's disease. These methods are premised in part on the availability of large amounts of human acid alpha glucosidase in a form that is catalytically active and in a form that can be taken up by tissues, particularly, liver, heart and muscle (e.g., smooth muscle, striated muscle, and cardiac muscle), of a patient being treated.
  • human acid alpha-glucosidase is provided from e.g., the transgenic animals described in the Examples.
  • the alpha-glucosidase is preferably predominantly (i.e., >50%) in the precursor form of about 100-110 kD.
  • the apparent molecular weight or relative mobility of the 100-110 kD precursor may vary somewhat depending on the method of analysis used, but is typically within the range 95 kD and 120 kD.
  • human acid alpha-glucosidase in the transgenic animals discussed in the Examples, it is possible that other sources of human alpha-glucosidase, such as resulting from cellular expression systems, can also be used.
  • an alternative way to produce human acid ⁇ -glucosidase is to transfect the acid ⁇ -glucosidase gene into a stable eukaryotic cell line (e.g., CHO) as a cDNA or genomic construct operably linked to a suitable promoter.
  • a stable eukaryotic cell line e.g., CHO
  • compositions of the present invention are usually administered intravenously. Intradermal, intramuscular or oral administration is also possible in some circumstances.
  • the compositions can be administered for prophylactic treatment of individuals suffering from, or at risk of, a lysosomal enzyme deficiency disease.
  • the pharmaceutical compositions are administered to a patient suffering from established disease in an amount sufficient to reduce the concentration of accumulated metabolite and/or prevent or arrest further accumulation of metabolite.
  • the pharmaceutical compositions are administered prophylactically in an amount sufficient to either prevent or inhibit accumulation of metabolite. An amount adequate to accomplish this is defined as a “therapeutically-” or “prophylactically-effective dose.” Such effective dosages will depend on the severity of the condition and on the general state of the patient's health.
  • human acid alpha glucosidase is usually administered at a dosage of 10 mg/kg patient body weight or more per week to a patient. Often dosages are greater than 10 mg/kg per week. Dosages regimes can range from 10 mg/kg per week to at least 1000 mg/kg per week. Typically dosage regimes are 10 mg/kg per week, 15 mg/kg per week, 20 mg/kg per week, 25 mg/kg per week, 30 mg/kg per week, 35 mg/kg per week, 40 mg/kg week, 45 mg/kg per week, 60 mg/kg week, 80 mg/kg per week and 120 mg/kg per week.
  • 10 mg/kg, 15 mg/kg, 20 mg/kg, 30 mg/kg or 40 mg/kg is administered once, twice or three times weekly. Treatment is typically continued for at least 4 weeks, sometimes 24 weeks, and sometimes for the life of the patient. Treatment is preferably administered i.v.
  • levels of human alpha-glucosidase are monitored following treatment (e.g., in theplasma or muscle) and a further dosage is administered when detected levels fall substantially below (e.g., less than 20%) of values in normal persons.
  • human acid alpha glucosidase is administered at an initially “high” dose (i.e., a “loading dose”), followed by administration of a lower doses (i.e., a “maintenance dose”).
  • a loading dose is at least about 40 mg/kg patient body weight 1 to 3 times per week (e.g., for 1, 2, or 3 weeks).
  • An example of a maintenance dose is at least about 5 to at least about 10 mg/kg patient body weight per week, or more, such as 20 mg/kg per week, 30 mg/kg per week, 40 mg/kg week.
  • a dosage is administered at increasing rate during the dosage period. Such can be achieved by increasing the rate of flow intravenous infusion or by using a gradient of increasing concentration of alpha-glucosidase administered at constant rate. Administration in this manner reduces the risk of immunogenic reaction.
  • the rate of administration measured in units of alpha glucosidase per unit time increases by at least a factor of ten.
  • the intravenous infusion occurs over a period of several hours (e.g., 1-10 hours and preferably 2-8 hours, more preferably 3-6 hours), and the rate of infusion is increased at intervals during the period of administration.
  • Suitable dosages for infusion at increasing rates are shown in table 1 below.
  • the first column of the table indicates periods of time in the dosing schedule. For example, the reference to 0-1 hr refers to the first hour of the dosing.
  • the fifth column of the table shows the range of doses than can be used at each time period.
  • the fourth column shows a narrower included range of preferred dosages.
  • the third column indicates upper and lower values of dosages administered in an exemplary clinical trial.
  • the second column shows particularly preferred dosages, these representing the mean of the range shown in the third column of table 1.
  • the disease shows a rapidly progressive course leading to cardiorespiratory failure within the first year of life.
  • lysosomal glycogen storage is observed in various tissues, and is most pronounced in heart and skeletal muscle.
  • Treatment with human acid alpha glucosidase in the present methods results in a prolongation of life of such patients (e.g., greater than 1, 2, 5 years up to a normal lifespan).
  • Treatment can also result in elimination or reduction of clinical and biochemical characteristics of Pompe's disease as discussed above.
  • Treatment is administered soon after birth, or antenatally if the parents are known to bear variant alpha glucosidase alleles placing their progeny at risk.
  • Pulmonary infections in combination with wasting of the respiratory muscles are life threatening and mostly become fatal before the third decade.
  • Treatment with the present methods prolongs the life of patients with late onset juvenile or adult Pompe's disease up to a normal life span. Treatment also eliminates or significantly reduces clinical and biochemical symptoms of disease.
  • Lysosomal proteins produced in the milk of transgenic animals have a number of other uses.
  • ⁇ -glucosidase in common with other ⁇ -amylases, is an important tool in production of starch, beer and pharmaceuticals. See Vihinen & Mantsala, Crit. Rev. Biochem. Mol. Biol. 24, 329-401 (1989) (incorporated by reference in its entirety for all purpose).
  • Lysosomal proteins are also useful for producing laboratory chemicals or food products.
  • acid ⁇ -glucosidase degrades 1,4 and 1,6 ⁇ -glucidic bonds and can be used for the degradation of various carbohydrates containing these bonds, such as maltose, isomaltose, starch and glycogen, to yield glucose.
  • Acid ⁇ -glucosidase is also useful for administration to patients with an intestinal maltase or isomaltase deficiency. Symptoms otherwise resulting from the presence of undigested maltose are avoided.
  • the enzyme can be administered without prior fractionation from milk, as a food product derived from such milk (e.g., ice cream or cheese) or as a pharmaceutical composition.
  • Purified recombinant lysosomal enzymes are also useful for inclusion as controls in diagnostic kits for assay of unknown quantities of such enzymes in tissue samples.
  • the 3.3-kb cDNA-fragment could be excised by ClaI and XhoI. This fragment was inserted into the expression cassette shown in FIG. 1 at the ClaI site and XhoI-compatible SalI site.
  • the expression plasmid p16,8 ⁇ glu consists of the cDNA sequence encoding human acid ⁇ -glucosidase flanked by bovine ⁇ S1-casein sequences as shown in FIG. 1.
  • the 27.3-kb fragment containing the complete expression cassette can be excised by cleavage with NotI (see FIG. 1).
  • Construct c8 ⁇ gluex1 contains the human acid ⁇ -glucosidase gene (Hoefsloot et al., Biochem. J. 272, 493-497 (1990)); starting in exon 1 just downstream of its transcription initiation site (see FIG. 2, panel A). Therefore, the construct encodes almost a complete 5′ UTR of the human acid ⁇ -glucosidase gene. This fragment was fused to the promoter sequences of the bovine ⁇ S1-casein gene. The ⁇ S1-casein initiation site is present 22 bp upstream of the ⁇ S1-casein/acid ⁇ -glucosidase junction.
  • the construct has the human acid ⁇ -glucosidase polyadenylation signal and 3′ flanking sequences.
  • Construct c8 ⁇ gluex2 contains the bovine ⁇ S1-casein promoter immediately fused to the translation initiation site in exon 2 of the human acid ⁇ -glucosidase gene (see FIG. 2, panel B).
  • the ⁇ S1-casein transcription initiation site and the ⁇ -glucosidase translation initiation site are 22-bp apart in this construct. Therefore no ⁇ -glucosidase 5′ UTR is preserved.
  • This construct also contains the human acid ⁇ -glucosidase polyadenylation signal and 3′ flanking sequences as shown in FIG. 2, panel B.
  • Construct c8,8 ⁇ gluex2-20 differs from construct c8 ⁇ gluex2 only in the 3′ region.
  • a SphI site in exon 20 was used to fuse the bovine ⁇ S1-casein 3′ sequence to the human acid ⁇ -glucosidase construct.
  • the polyadenylation signal is located in this 3′ ⁇ S1-casein sequence (FIG. 2, panel C).
  • Construct c8,8 ⁇ gluex2-20 differs from construct c8 ⁇ gluex2 only in the 3′ region.
  • a SphI site in exon 20 was used to fuse the bovine ⁇ S1-casein 3′ sequence to the human acid ⁇ -glucosidase construct.
  • the polyadenylation signal is located in this 3′ ⁇ S1-casein sequence (FIG. 2, panel C).
  • This ligation resulted in two orientations of the fragments generating plasmids p7.3 ⁇ gluBES, p7.3 ⁇ gluBSE, p8.5 ⁇ gluBSE, p8.5 ⁇ gluBES, p10 ⁇ gluBSE and p10 ⁇ gluBES.
  • pKUN10 ⁇ C (i.e., a derivative of pKUN8 ⁇ C) was obtained by digesting pKUN8 ⁇ C with NotI, filling in the sticky ends with Klenow and subsequently, annealing the plasmid by blunt-ended ligation. Finally, p10 ⁇ glu ⁇ NV was digested with NotI. These sticky ends were also filled with Klenow and the fragment was ligated, resulting in plasmid p10 ⁇ glu ⁇ NotI.
  • the next step was the ligation of the 3′ part to p5′ ⁇ gluex1.
  • p10 ⁇ glu ⁇ N was digested with BglII and BamHI. This fragment containing exon 16-20 was isolated.
  • p5′ ⁇ gluex1 was digested with BglII and to prevent self-ligation, and treated with phosphorylase (BAP) to dephosphorylate the sticky BglII ends. Since BamHI sticky ends are compatible with the BglII sticky ends, these ends ligate to each other.
  • BAP phosphorylase
  • the resulting plasmid i.e., p5′3′ ⁇ gluex1 was selected. This plasmid has a unique BglII site available for the final construction step (see FIG. 3, panels B and C).
  • the bovine ⁇ S1-casein promoter sequences were incorporated in the next step via a ligation involving three fragments.
  • the pWE15 cosmid vector was digested with NotI and dephosphorylated.
  • the bovine ⁇ S1-casein promoter was isolated as an 8 Rb NotI-ClaI fragment (see de Boer et al., 1991, supra).
  • the human acid ⁇ -glucosidase fragment was isolated from p ⁇ gluex1 using the same enzymes. These three fragments were ligated and packaged using the Stratagene GigapackII kit in 1046 E. coli host cells.
  • the resulting cosmid c8 ⁇ gluex1 was propagated in E. coli strain DH5 ⁇ .
  • the vector was linearized with NotI before microinjection.
  • the construction of the other two expression plasmids followed a similar strategy to that of c8 ⁇ gluex1.
  • the plasmid p5′ ⁇ gluStuI was derived from p8,5 ⁇ gluBSE by digestion of the plasmid with StuI, followed by self-ligation of the isolated fragment containing exon 2-3 plus the vector sequences. Plasmid p5′ ⁇ gluStuI was digested with PglII followed by a partial digestion of the linear fragment with NcoI resulting in several fragments.
  • pKUN12 ⁇ C is a derivative of pKUN8 ⁇ C containing the polylinker: ClaI NcoI BglII HindIII EcoRI SphI XhoI SmaI/SfiI NotI.
  • the plasmid p10 ⁇ glu ⁇ NotI was digested with BglII and HindIII.
  • the fragment containing exons 16-20 was isolated and ligated in p5′ ⁇ gluex2 digested with BglIII and HindIII.
  • the resulting plasmid was p5′3′ ⁇ gluex2.
  • the middle fragment in p5′3′ ⁇ gluex2 was inserted as for p ⁇ gluex1.
  • p7.3 ⁇ glu was digested with BglII.
  • the fragment was isolated and ligated to the BglII-digested and dephosphorylated p5′3′ ⁇ gluex2.
  • the resulting plasmid, p ⁇ gluex2 was used in construction of c8 ⁇ gluex-20 and c8,8 ⁇ gluex2-20 (FIG. 2, panels B and C).
  • the final step in generating c8,8 ⁇ gluex2-20 was the ligation of three fragments as in the final step in the construction leading to c8 ⁇ gluex1. Since the ClaI site in p ⁇ gluex2-20-3′ ⁇ S1 and p ⁇ gluex2 appeared to be uncleavable due to methylation, the plasmids had to be propagated in the E. coli DAM( ⁇ ) strain ECO343. The p ⁇ gluex2-20-3′ ⁇ S1 isolated from that strain was digested with ClaI and NotI. The fragment containing exons 2-20 plus the 3′ ⁇ S1-casein flanking region was purified from the vector sequences.
  • This fragment an 8 kb NotI-ClaI fragment containing the bovine ⁇ s1 promoter (see DeBoer (1991) & (1993), supra) and NotI-digested, dephosphorylated pWE15 were ligated and packaged.
  • the resulting cosmid is c8,8 ⁇ gluex2-20.
  • Cosmid c8 ⁇ gluex2 (FIG. 2, panel B) was constructed via a couple of different steps. First, cosmid c8,8 ⁇ gluex2-20 was digested with SalI and NotI. The 10.5-kb fragment containing the ⁇ S1-promoter and the exons 2-6 part of the acid ⁇ -glucosidase gene was isolated. Second, plasmid p ⁇ gluex2 was digested with SalI and NotI to obtain the fragment containing the 3′ part of the acid ⁇ -glucosidase gene. Finally, the cosmid vector pWE15 was digested with NotI and dephosphorylated. These three fragments were ligated and packaged. The resulting cosmid is c8 ⁇ gluex2.
  • the cDNA and genomic constructs were linearized with NotI and injected in the pronucleus of fertilized mouse oocytes which were then implanted in the uterus of pseudopregnant mouse foster mothers.
  • the offspring were analyzed for the insertion of the human ⁇ -glucosidase cDNA or genomic DNA gene construct by Southern blotting of DNA isolated from clipped tails. Transgenic mice were selected and bred.
  • mice containing the cDNA construct varied from 0.2 to 2 ⁇ mol/ml per hr.
  • the mouse lines containing the genomic construct (FIG. 2, panel A) expressed at levels from 10 to 610 ⁇ mol/ml per hr.
  • the recombinant acid ⁇ -glucosidase was isolated from the milk of transgenic mice, by sequential chromatography of milk on ConA-SepharoseTM and SephadexTM G200. 7 ml milk was diluted to 10 ml with 3 ml Con A buffer consisting of 10 mM sodium phosphate, pH 6.6 and 100 mM NaCl. A 1:1 suspension of Con A sepharose in Con A buffer was then added and the milk was left overnight at 4° C. with gentle shaking.
  • Con A sepharose beads were then collected by centrifugation and washed 5 times with Con A buffer, 3 times with Con A buffer containing 1 M NaCl instead of 100 mM, once with Con A buffer containing 0.5 M NaCl instead of 100 mM and then eluted batchwise with Con A buffer containing 0.5 M NaCl and 0.1 M methyl- ⁇ -D-mannopyranoside.
  • the acid ⁇ -glucosidase activity in the eluted samples was measured using the artificial 4-methyl-umbelliferyl- ⁇ -D-glycopyranoside substrate (see above).
  • Fractions containing acid ⁇ -glucosidase activity were pooled, concentrated and dialyzed against Sephadex buffer consisting of 20 mM Na acetate, pH 4.5 and 25 mM NaCl, and applied to a SephadexTM 200 column. This column was run with the same buffer, and fractions were assayed for acid ⁇ -glucosidase activity and protein content. Fractions rich in acid ⁇ -glucosidase activity and practically free of other proteins were pooled and concentrated. The method as described is essentially the same as the one published by Reuser et al., Exp. Cell Res. 155:178-179 (1984). Several modifications of the method are possible regarding the exact composition and pH of the buffer systems and the choice of purification steps in number and in column material.
  • Acid ⁇ -glucosidase purified from the milk was then tested for phosphorylation by administrating the enzyme to cultured fibroblasts from patients with GSD II (deficient in endogenous acid ⁇ -glucosidase).
  • GSD II deficient in endogenous acid ⁇ -glucosidase
  • mannose 6-phosphate containing proteins are bound by mannose 6-phosphate receptors on the cell surface of fibroblasts and are subsequently internalized. The binding is inhibited by free mannose 6-phosphate (Reuser et al., Exp. Cell Res. 155:178-189 (1984)).
  • the acid ⁇ -glucosidase was added to 104-106 fibroblasts in 500 ⁇ l culture medium (Ham F10, supplied with 10% fetal calf serum and 3 mM Pipes) in an amount sufficient to metabolize 1 ⁇ mole 4-methyl-umbelliferyl- ⁇ -D-glucopyranoside per hour for a time period of 20 hours.
  • the experiment was performed with or without 5 mM mannose 6-phosphate as a competitor, essentially as described by Reuser et al., supra (1984).
  • enzyme was injected in the tail vein of groups of two or three KO mice, once a week for periods of up to 25 weeks.
  • the initial dose was 2 mg (68 mg/kg) followed by 0.5 mg (17 mg/kg)/mouse for 12 weeks.
  • Injections started when the mice were 6-7 months of age. At this age, clear histopathology has developed in the KO model.
  • Two days after the last enzyme administration the animals were killed, and the organs were perfused with phosphate buffered saline (PBS). Tissue homogenates were made for AGLU enzyme activity assays and tissue glycogen content, and sections of various organs were made to visualize (via light microscopy) lysosomal glycogen accumulation.
  • PBS phosphate buffered saline
  • mice treated 13 weeks with 0.5 mg/mouse (Group A, 3 animals/Group) had an increase of activity in the liver and spleen and decreased levels of glycogen in liver and perhaps in heart.
  • One animal showed increased activity in muscles, although there was no significant decrease of glycogen in muscle.
  • mice that were treated 14 weeks with 0.5 mg/mouse followed by 4 weeks with 2 mg/mouse showed similar results to those treated for 13 weeks only, except that an increased activity was measured in the heart and skeletal muscles and decreases of glycogen levels were also seen in the spleen.
  • mice that were treated 14 weeks with 0.5 mg/mouse followed by 11 weeks with 2 mg/mouse showed similar results to the other two groups except that treated mice showed definite decreases in glycogen levels in liver, spleen, heart and skeletal muscle. No activity could be detected, even at the highest dose, in the brain.
  • a single phase I study (AGLU1101-01) has been conducted in 15 healthy male volunteers. Doses of AGLU ranged from 25 to 800 mg, administered by intravenous infusion to healthy male adult volunteers. Subjects with a history of allergies and hypersensitivities were excluded from the study. The subjects were randomized into dose groups of 5, and each dose Group received AGLU (4 subjects) or placebo (1 subject) at each dose level. All subjects received two doses of study drug, which were administered two weeks apart. The dosing regimen was as follows:
  • Subjects were administered AGLU or placebo as an infusion on Day 1 of each treatment period.
  • the infusions were administered over a 30 minute period and subjects were kept in a semi-recumbent position for at least 2 hours after cessation of infusion.
  • Adverse events were recorded just before the start of the infusion, at 30 minutes (end of infusion) and at 3, 12, 24, 36 and 48 hours thereafter as well as on Days 5 and 8 (first period) and days 5, 8 and 15 (second period). Vital signs, ECG and physical examinations were also monitored regularly throughout the treatment period.
  • Adverse Event Reports Dose (mg) Adverse Events 25 The reported events were muscle weakness, abnormal vision and fatigue. All events were mild and were deemed unrelated to the test article by the investigator. 50 The reported events were headache, rhinitis, nose bleed and paresthesia. All events were mild and were deemed unrelated or remotely related to the test article by the investigator, except the paresthesia which was classed as moderate and was deemed possibly related to the test article. 100 The reported events were rhinitis, headache, fatigue, hematoma and injection site reaction.
  • a trial of the safety and efficacy of recombinant acid ⁇ -glucosidase as enzyme replacement therapy on infantile and juvenile patients with glycogen storage disease Type II is conducted.
  • Four infantile patients and three juvenile patients are recruited.
  • Infantiles are administered a starting dose of 15-20 mg/kg titrated to 40 mg/kg and juveniles are administered 10 mg/kg.
  • Patients are treated for 24 weeks.
  • a further phase II clinical trial is performed on eight patients aged ⁇ 6 months of age within 2 months after diagnosis at a dosage of 40 mg/kg. Patients are treated for 24 weeks and evaluated by the following criteria:
  • Efficacy can be show by a 50% survival at 6 months post-diagnosis without life saving interventions in the ⁇ -glucosidase group compared to 10% survival in the historical control group in combination with a BSID II classified as normal or mildly delayed.
  • a further clinical trial is performed on juvenile patients.
  • the patients are aged >1 year and ⁇ 35 years of age with juvenile onset of GSD type IIb
  • the patients are administered 10 mg/kg or 20 mg/kg for a period of twenty-four weeks treatment.
  • Treatment is monitored by the following parameters.
  • Safety parameters Laboratory safety data
  • Adverse event recording Primary efficacy Pulmonary function parameters (e.g. FVC, time on ventilator) Muscle strength
  • Secondary efficacy Life-saving interventions parameters Quality of life Skeletal muscle acid ⁇ -glucosidase activity Quantitative objective 20% relative improvement in primary efficacy parameters over baseline
  • All quantitative measurements relating to efficacy are preferably statistically significant relative to contemporaneous or historical controls, preferably at p ⁇ 0.05.
  • Alpha-glucosidase is formulated as follows: 5 mg/ml ⁇ -Glu, 15 mM sodium phosphate, pH 6.5, 2% (w/w) mannitol, and 0.5% (w/w) sucrose.
  • the above formulation is filled to a final volume of 10.5 ml into a 20 cc tubing vial and lyophilized.
  • each vial is reconstituted with 10.3 ml* of sterile saline (0.9%) for injection (USP or equivalent.) to yield 10.5 ml of a 5 mg/ml ⁇ -Glu solution that may be directly administered or subsequently diluted with sterile saline to a patient specific target dose concentration.
  • the 10.5 ml fill (52.5 mg alpha glucosidase total in vial) includes the USP recommended overage, that allows extraction and delivery (or transfer) of 10 mls (50 mg).
  • the mannitol serves as a suitable bulking agent shortening the lyophilization cycle (relative to sucrose alone).
  • the sucrose serves as a cryo/lyoprotectant resulting in no significant increase in aggregation following reconstitution. Reconstitution of the mannitol (only) formulations had repeatedly resulted in a slight increase in aggregation. Following lyophilization, the cake quality was acceptable and subsequent reconstitution times were significantly reduced Saline is preferred to HSA/dextrose for infusion solution.
  • saline When saline is used in combination with lyophilization in 2% mannitol/0.5% sucrose the solution has acceptable tonicity for intravenous administration.
  • the lyophilized vials containing the 2% mannitol/0.5% sucrose formulation were reconstituted with 0.9% sterile saline (for injection) to yield 5 mg/ml ⁇ -Glu.
  • the solution is administered via the indwelling intravenous cannula. Patients are monitored closely during the infusion period and appropriate clinical intervention are taken in the event of an adverse event or suspected adverse event. A window of 48 hours is allowed for each infusion. An infusion schedule in which the rate of infusion increases with time reduces or eliminates adverse events.
  • Infusions for infantiles can be administered according to the following schedule:
  • Infusions for juveniles can be administered according to the following schedule:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Husbandry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
US09/454,711 1995-08-02 1999-12-06 Treatment of pompe's disease Abandoned US20030007963A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US09/454,711 US20030007963A1 (en) 1998-12-07 1999-12-06 Treatment of pompe's disease
US10/611,598 US7351410B2 (en) 1995-08-02 2003-06-30 Treatment of Pompe's disease
US12/012,003 US7655226B2 (en) 1995-08-02 2008-01-30 Treatment of Pompe's disease
US12/633,932 US20100092449A1 (en) 1998-12-07 2009-12-09 Treatment of Pompe's Disease
US13/333,052 US20130039901A1 (en) 1998-12-07 2011-12-21 Treatment of Pompe's Disease
US13/886,573 US20140037611A1 (en) 1998-12-07 2013-05-03 Treatment of Pompe's Disease
US14/863,333 US20160243203A1 (en) 1998-12-07 2015-09-23 Treatment of pompe's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11129198P 1998-12-07 1998-12-07
US09/454,711 US20030007963A1 (en) 1998-12-07 1999-12-06 Treatment of pompe's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/611,598 Continuation US7351410B2 (en) 1995-08-02 2003-06-30 Treatment of Pompe's disease

Publications (1)

Publication Number Publication Date
US20030007963A1 true US20030007963A1 (en) 2003-01-09

Family

ID=22337648

Family Applications (7)

Application Number Title Priority Date Filing Date
US09/454,711 Abandoned US20030007963A1 (en) 1995-08-02 1999-12-06 Treatment of pompe's disease
US10/611,598 Expired - Lifetime US7351410B2 (en) 1995-08-02 2003-06-30 Treatment of Pompe's disease
US12/012,003 Expired - Fee Related US7655226B2 (en) 1995-08-02 2008-01-30 Treatment of Pompe's disease
US12/633,932 Abandoned US20100092449A1 (en) 1998-12-07 2009-12-09 Treatment of Pompe's Disease
US13/333,052 Abandoned US20130039901A1 (en) 1998-12-07 2011-12-21 Treatment of Pompe's Disease
US13/886,573 Abandoned US20140037611A1 (en) 1998-12-07 2013-05-03 Treatment of Pompe's Disease
US14/863,333 Abandoned US20160243203A1 (en) 1998-12-07 2015-09-23 Treatment of pompe's disease

Family Applications After (6)

Application Number Title Priority Date Filing Date
US10/611,598 Expired - Lifetime US7351410B2 (en) 1995-08-02 2003-06-30 Treatment of Pompe's disease
US12/012,003 Expired - Fee Related US7655226B2 (en) 1995-08-02 2008-01-30 Treatment of Pompe's disease
US12/633,932 Abandoned US20100092449A1 (en) 1998-12-07 2009-12-09 Treatment of Pompe's Disease
US13/333,052 Abandoned US20130039901A1 (en) 1998-12-07 2011-12-21 Treatment of Pompe's Disease
US13/886,573 Abandoned US20140037611A1 (en) 1998-12-07 2013-05-03 Treatment of Pompe's Disease
US14/863,333 Abandoned US20160243203A1 (en) 1998-12-07 2015-09-23 Treatment of pompe's disease

Country Status (16)

Country Link
US (7) US20030007963A1 (es)
EP (2) EP2020438B1 (es)
JP (7) JP4990434B2 (es)
KR (1) KR20010101131A (es)
AT (1) ATE410506T1 (es)
AU (1) AU3113700A (es)
BE (1) BE2018C038I2 (es)
CA (1) CA2353522A1 (es)
CY (2) CY1121113T1 (es)
DE (2) DE122009000018I1 (es)
DK (2) DK1137762T3 (es)
ES (2) ES2677343T3 (es)
LU (1) LU91544I2 (es)
NL (1) NL300382I2 (es)
PT (2) PT2020438T (es)
WO (1) WO2000034451A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070223290A1 (en) * 2004-12-10 2007-09-27 Dong-Woo Sohn Low power multi-chip semiconductor memory device and chip enable method thereof

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2677343T3 (es) * 1998-12-07 2018-08-01 Genzyme Corporation Tratamiento de la enfermedad de Pompe
CA2398995C (en) * 2000-02-04 2014-09-23 Children's Hospital Research Foundation Lipid hydrolysis therapy for atherosclerosis and related diseases
AU2016256663A1 (en) * 2000-07-18 2016-11-24 Duke University Treatment of clycogen storage disease type II
ATE355075T1 (de) * 2000-07-18 2006-03-15 Univ Duke Behandlung der glykogenspeicherkrankheit typ ii
EP1782825B1 (en) * 2000-07-18 2014-09-10 Duke University Treatment of glycogen storage diseases type II
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ES2300439T3 (es) * 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
WO2004064750A2 (en) 2003-01-22 2004-08-05 Duke University Improved constructs for expressing lysosomal polypeptides
SI2444102T1 (sl) * 2003-01-31 2015-08-31 Mount Sinai School Of Medicine Of New York University Kombinirana terapija za zdravljenje motenj pomanjkanja proteina
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
AU2006247065B8 (en) 2005-05-17 2012-07-12 Amicus Therapeutics, Inc. A method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives
WO2007030375A2 (en) * 2005-09-08 2007-03-15 Children's Hospital Medical Center Lysosomal acid lipase therapy for nafld and related diseases
JP2010509344A (ja) * 2006-11-13 2010-03-25 ザイストール セラピューティクス， インコーポレイテッド ポンペ病を治療するための方法
EP3187508A1 (en) 2008-05-07 2017-07-05 BioMarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
WO2010005565A2 (en) 2008-07-08 2010-01-14 Duke University Method of treating glycogen storage disease
EP2475376B1 (en) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
US8536148B2 (en) 2009-09-04 2013-09-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Disabling autophagy as a treatment for lysosomal storage diseases
PL3205351T3 (pl) 2010-04-23 2023-08-28 Alexion Pharmaceuticals, Inc. Enzym na lizosomalną chorobę spichrzeniową
IL291554B2 (en) 2010-06-25 2024-02-01 Shire Human Genetic Therapies Administering therapeutic agents to the central nervous system
JP6045493B2 (ja) 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アリールスルファターゼａのｃｎｓ送達の方法および組成物
ES2643015T3 (es) 2010-06-25 2017-11-21 Shire Human Genetic Therapies, Inc. Tratamiento del Síndrome de Sanfilippo Tipo B
NZ702808A (en) 2010-06-25 2016-08-26 Shire Human Genetic Therapies Methods and compositions for cns delivery of iduronate-2-sulfatase
DK3103469T3 (en) 2010-06-25 2021-02-22 Shire Human Genetic Therapies Indgivelse af terapeutiske midler til centralnervesystemet
BR112012033197A2 (pt) 2010-06-25 2017-06-06 Shire Human Genetic Therapies métodos e composições para liberação de cns de n-sulfatase de heparano.
SG188456A1 (en) 2010-09-09 2013-04-30 Synageva Biopharma Corp Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
KR20140006037A (ko) 2011-02-15 2014-01-15 시나게바 바이오파르마, 코포레이션 리소좀의 산 리파제 결핍을 치료하는 방법들
CN103443273B (zh) 2011-03-16 2016-10-26 天野酶制品株式会社 修饰型α-葡萄糖苷酶及其用途
PE20140617A1 (es) * 2011-04-22 2014-05-28 Genzyme Corp Alfa glucosidasa acida modificada con procesamiento acelerado
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
MX349992B (es) 2012-03-07 2017-08-22 Amicus Therapeutics Inc Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe.
WO2014130723A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
US10603364B2 (en) 2014-08-11 2020-03-31 Shire Human Genetic Therapies, Inc. Lysosomal targeting and uses thereof
SG10202003753PA (en) 2014-09-30 2020-05-28 Amicus Therapeutics Inc Highly potent acid alpha-glucosidase with enhanced carbohydrates
MA41022A (fr) 2014-11-24 2017-10-03 Shire Human Genetic Therapies Ciblage lysosomial et utilisations correspondantes
US20180326021A1 (en) * 2015-08-31 2018-11-15 Duke University Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders
WO2017049157A1 (en) 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
WO2017117407A1 (en) 2015-12-30 2017-07-06 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease
BR112018070189A2 (pt) 2016-03-30 2019-02-19 Amicus Therapeutics, Inc. método para seleção de proteínas recombinantes ricas em m6p
BR112018069965A2 (pt) 2016-03-30 2019-01-29 Amicus Therapeutics Inc formulações compreendendo alfa-glucosidase ácida recombinante
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
CN110050063B (zh) 2016-09-12 2023-11-03 吉尼松公司 酸性α-葡萄糖苷酶变体及其用途
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
CN119113091A (zh) 2017-05-15 2024-12-13 阿米库斯治疗学公司 重组人类酸性α-葡萄糖苷酶
EP3996696A1 (en) 2019-07-09 2022-05-18 Genethon Treatment of glycogen storage disease (gsd)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832981A1 (en) * 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
CA2351200A1 (en) 1989-12-01 1991-06-13 Gene Pharming Europe Bv Production of recombinant polypeptides by bovine species and transgenic methods
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
JP3670003B2 (ja) * 1992-06-15 2005-07-13 ファーミング ビー．ブイ． ウシ種による組み換えポリペプチドの製造及びトランスジェニック法
TW319781B (es) * 1993-05-17 1997-11-11 Nippon Painting Co Ltd
AT1470U1 (de) 1995-08-01 1997-05-26 Austria Card Laminierte karte und verfahren zu ihrer herstellung
US6118045A (en) * 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
ES2677343T3 (es) * 1998-12-07 2018-08-01 Genzyme Corporation Tratamiento de la enfermedad de Pompe

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070223290A1 (en) * 2004-12-10 2007-09-27 Dong-Woo Sohn Low power multi-chip semiconductor memory device and chip enable method thereof

Also Published As

Publication number Publication date
ES2312222T3 (es) 2009-02-16
CY2018020I2 (el) 2019-07-10
US20130039901A1 (en) 2013-02-14
US20080206223A1 (en) 2008-08-28
JP2019172685A (ja) 2019-10-10
CY2018020I1 (el) 2019-07-10
DK1137762T3 (da) 2009-02-02
DE122009000018I1 (de) 2009-09-17
CY1121113T1 (el) 2019-07-10
JP2012224643A (ja) 2012-11-15
EP2020438B1 (en) 2018-04-11
BE2018C038I2 (es) 2019-03-05
US20140037611A1 (en) 2014-02-06
PT2020438T (pt) 2018-07-13
US20160243203A1 (en) 2016-08-25
NL300382I2 (en) 2009-12-01
US20040081645A1 (en) 2004-04-29
JP4990434B2 (ja) 2012-08-01
KR20010101131A (ko) 2001-11-14
DK2020438T3 (en) 2018-07-23
EP2020438A1 (en) 2009-02-04
EP1137762A1 (en) 2001-10-04
JP2002531581A (ja) 2002-09-24
JP2015134836A (ja) 2015-07-27
JP2018115200A (ja) 2018-07-26
NL300382I1 (nl) 2009-06-02
CA2353522A1 (en) 2000-06-15
US20100092449A1 (en) 2010-04-15
AU3113700A (en) 2000-06-26
DE69939705D1 (de) 2008-11-20
US7655226B2 (en) 2010-02-02
US7351410B2 (en) 2008-04-01
WO2000034451A1 (en) 2000-06-15
JP2009161562A (ja) 2009-07-23
ES2677343T3 (es) 2018-08-01
PT1137762E (pt) 2009-01-14
EP1137762A4 (en) 2005-01-12
LU91544I2 (fr) 2009-05-25
ATE410506T1 (de) 2008-10-15
JP2017066160A (ja) 2017-04-06
EP1137762B1 (en) 2008-10-08

Similar Documents

Publication Publication Date Title
US7655226B2 (en) Treatment of Pompe's disease
US6118045A (en) Lysosomal proteins produced in the milk of transgenic animals
US20020157123A1 (en) Compositions and methods for treating enzyme deficiency
US20020073438A1 (en) Methods of purifying human acid alpha-glucosidase
US20040161837A1 (en) Methods of purifying human acid alpha-glucosidase
AU2005200636B2 (en) Lysosomal proteins produced in the milk of transgenic animals
EP1262191A1 (en) Pharmaceutical compositions comprising recombinant human acid alpha-glucosidase containing mannose 6-phosphate
NZ501784A (en) Transgenic nonhuman mammals capable of secreting a lysosomal protein containing mannose 6-phosphate into milk

Legal Events

Date Code Title Description
AS Assignment

Owner name: PHARMING B.V., NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VAN BREE, JOHANNES B.M.M.;VENNEKER, EDNA H.G.;REEL/FRAME:010749/0076

Effective date: 20000223

Owner name: GENZYME CORPORATION, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEEKER, DAVID P.;REEL/FRAME:010749/0060

Effective date: 20000321

AS Assignment

Owner name: PHARMING INTELLECTUAL PROPERTY B.V., NETHERLANDS

Free format text: CORRECTED COVER SHEET TO CORRECT ASSIGNEE NAME, PREVIOUSLY RECORDED AT REEL/FRAME 010749/0076 (ASSIGNMENT OF ASSIGNOR'S INTEREST);ASSIGNORS:VAN BREE, JOHANNES B.M.M.;VENNEKER, EDNA H.G.;REEL/FRAME:014338/0817;SIGNING DATES FROM 20000221 TO 20000223

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: GENZYME CORPORATION, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PHARMING INTELLECTUAL PROPERTY B.V.;REEL/FRAME:018581/0317

Effective date: 20061121